Department of Conservative Dentistry and Periodontology, University Hospital, LMU Munich, Goethestrasse 70, 80336, Munich, Germany.
Department of Conservative Dentistry and Periodontology, University Hospital, LMU Munich, Goethestrasse 70, 80336, Munich, Germany.
Anaerobe. 2021 Oct;71:102439. doi: 10.1016/j.anaerobe.2021.102439. Epub 2021 Aug 25.
Antimicrobial peptides are receiving increasing attention as potential therapeutic agents for treating biofilm-related infections of the oral cavity. Many bacteria residing in biofilms exhibit an enhanced antibiotic tolerance, which grants intrinsically susceptible microorganisms to survive lethal concentrations of antibiotics. In this study, we examined the effects of two endogenous human antimicrobial peptides, LL-37 and human Lactoferricin, on the antibiotic drug efficacy of amoxicillin, clindamycin and metronidazole in two types of polymicrobial biofilms, which aimed to represent frequent oral diseases: (1) facultative anaerobic (Streptococcus mutans, Streptococcus sanguinis, Actinomyces naeslundii) and (2) obligate anaerobic biofilms (Veillonella parvula, Parvimonas micra, Fusobacterium nucleatum). LL-37 and Lactoferricin enhanced the anti-biofilm effect of amoxicillin and clindamycin in facultative anaerobic biofilms. Metronidazole alone was ineffective against facultative anaerobic biofilms, but the presence of LL-37 and Lactoferricin led to a greater biofilm reduction. Obligate anaerobic biofilms showed an increased drug tolerance to amoxicillin and clindamycin, presumably due to metabolic downshifts of the bacteria residing within the biofilm. However, when combined with LL-37 or Lactoferricin, the reduction of obligate anaerobic biofilms was markedly enhanced for all antibiotics, even for amoxicillin and clindamycin. Furthermore, our results suggest that antimicrobial peptides enhance the dispersion of matured biofilms, which may be one of their mechanisms for targeting biofilms. In summary, our study proves that antimicrobial peptides can serve as an auxiliary treatment strategy for combatting enhanced antibiotic tolerance in bacterial biofilms.
抗菌肽作为治疗口腔生物膜相关感染的潜在治疗剂受到越来越多的关注。许多生活在生物膜中的细菌表现出增强的抗生素耐药性,这使得固有敏感的微生物能够在致死浓度的抗生素下存活。在这项研究中,我们研究了两种内源性人类抗菌肽(LL-37 和人乳铁蛋白)对阿莫西林、克林霉素和甲硝唑在两种多微生物生物膜中的抗生素药物疗效的影响,这两种生物膜旨在代表常见的口腔疾病:(1)兼性厌氧菌(变形链球菌、血链球菌、奈瑟氏放线菌)和(2)专性厌氧菌生物膜(小韦荣球菌、小韦荣球菌、核梭杆菌)。LL-37 和乳铁蛋白增强了阿莫西林和克林霉素在兼性厌氧菌生物膜中的抗生物膜作用。甲硝唑单独对兼性厌氧菌生物膜无效,但 LL-37 和乳铁蛋白的存在导致生物膜减少更多。专性厌氧菌生物膜对阿莫西林和克林霉素的药物耐受性增加,可能是由于生物膜内细菌的代谢下降。然而,当与 LL-37 或乳铁蛋白联合使用时,所有抗生素对专性厌氧菌生物膜的减少明显增强,甚至对阿莫西林和克林霉素也是如此。此外,我们的结果表明,抗菌肽增强了成熟生物膜的分散,这可能是它们靶向生物膜的机制之一。总之,我们的研究证明,抗菌肽可以作为一种辅助治疗策略,用于对抗细菌生物膜中增强的抗生素耐药性。